Orexin Receptors: Pharmacology and Therapeutic Opportunities
Tóm tắt
Orexin-A and -B (also known as hypocretin-1 and -2) are neuropeptides produced in the lateral hypothalamus that promote many aspects of arousal through the OX1 and OX2 receptors. In fact, they are necessary for normal wakefulness, as loss of the orexin-producing neurons causes narcolepsy in humans and rodents. This has generated considerable interest in developing small-molecule orexin receptor antagonists as a novel therapy for the treatment of insomnia. Orexin antagonists, especially those that block OX2 or both OX1 and OX2 receptors, clearly promote sleep in animals, and clinical results are encouraging: Several compounds are in Phase III trials. As the orexin system mainly promotes arousal, these new compounds will likely improve insomnia without incurring many of the side effects encountered with current medications.
Từ khóa
Tài liệu tham khảo
55. Gudewill S. 1992. Der Zusammenhang zwischen Schlaf-Wach-Verhalten und Hormonsekretion bei Narkolepsiepatienten. PhD thesis. Ludwig-Maximilians Univ., Munich
Kisanuki YY, 2000, The role of orexin receptor type-1 (OX1R) in the regulation of sleep
85. National Institutes of Health. 2005. National Institutes of Health State of the Science Conference Statement on manifestations and management of chronic insomnia in adults, June 13–15, 2005. Sleep 28:1049–57
Katz DA, 2002, J. Fam. Pract., 51, 229
Walsh JK, 1999, Sleep, 22, S386
107a. Herring WJ, Budd KS, Hutzelmann J, Snyder E, Snavely D, et al. 2010. Efficacy and tolerability of the dual orexin receptor antagonist MK-4305 in patients with primary insomnia: randomized, controlled, adaptive crossover polysomnography study. Presented at SLEEP 2010, 24th Annu. Meet. Assoc. Prof. Sleep Soc., June 5–9, San Antonio, Tex.
Di Fabio R, 2009, Bis-amido piperidine derivatives as in vitro and in vivo potent dual orexin receptor antagonists
114. Ratti E. 2007. Psychiatry: an innovative drug discovery pipeline. http://www.gsk.com/investors/presentations/2007/neurosciences-seminar-dec07/emiliangelo-ratti.pdf
116. Brisbare-Roch C, Clozel M, Jenck F. 2008. Effects of repeated oral administration of the orexin receptor antagonist almorexant in rats and dogs. Presented at SLEEP 2008, 22nd Annu. Meet. Assoc. Prof. Sleep Soc., June 7–12, Baltimore, Md.
117. Morairty S, Revel F, Moreau J, Silveira K, Malherbe P, et al. 2009. Further characterization of the hypocretin/orexin antagonist almorexant. Presented at Neuroscience 2009, Annu. Meet. Soc. Neurosci., Oct. 17–21, Chicago
123. Coleman P, Cox C, Breslin M, Schreier J, Roecker A, et al. 2010. Discovery of MK-4305: a novel orexin receptor antagonist for the treatment of insomnia. Presented at 239th ACS Natl. Meet., March 21–25, San Francisco
127. Dingemanse J, Dorffner G, Hajak G, Benes H, Danker-Hopfe H, et al. 2007. Proof-of-concept study in primary insomnia patients with almorexant(ACT-078573),a dual orexin receptor antagonist. Presented at WorldSleep07, 5th Int. Congr. World Fed. Sleep Res. Sleep Med. Soc., Sept. 2–6, Cairns, Aust.
128. GlaxoSmithKline. 2010. Product development pipeline. http://www.gsk.com/investors/product_pipeline/docs/GSK-product-pipeline-Feb-2010.pdf
134. Brisbare-Roch C, Feletti L, Koberstein R, Nayler O, Jenck F. 2007. Transient orexin receptor blockade induces sleep without cataplexy in rats. Presented at WorldSleep07, 5th Int. Congr. World Fed. Sleep Res. Sleep Med. Soc., Sept. 2–6, Cairns, Aust.
Hoever P, 2008, Multiple-dose pharmacokinetics, pharmacodynamics, safety, and tolerability of the orexin receptor antagonist almorexant in healthy subjects